NVLX $.1325 Nuvilex's pancreatic cancer treatment helped patients to a far better outcome than that previously reported with standard single-drug gemcitabine and even that reported for the just approved ABRAXANE-gemcitabine combination.

http://www.nuvilex.com/

Nuvilex has recently acquired worldwide exclusive rights to the live cell-encapsulation technology described above from SG Austria Pte. Ltd. for the development of treatments for any and all types of cancer. The rights to use the cancer drug-activating cells (22P1G cells) that will be part of Nuvilex’s treatment for advanced pancreatic cancer were also acquired.